69
Participants
Start Date
July 31, 2005
Primary Completion Date
February 28, 2009
Study Completion Date
December 31, 2009
Gemcitabine
1000mg/m2 30min IV, Day 1 \& 8
Docetaxel
30mg/m2, 30min IV, day 1 \& 8
Cetuximab
100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
Consultants in Medical Oncology and Hematology, Drexel Hill
Northeast Georgia Medical Center, Gainesville
Gainsville Hematology Oncology Associates, Gainesville
Florida Cancer Specialists, Fort Myers
Northeast Alabama Regional Medical Center, Anniston
Tennessee Oncology, PLLC, Nashville
Consultants in Blood Disorders and Cancer, Louisville
Graves-Gilbert Clinic, Bowling Green
Northeast Arkansas Clinic, Jonesboro
Mercy Hospital, Portland
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
SCRI Development Innovations, LLC
OTHER